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http:WHAT THIS PAPER ADDS
Remote ischemic preconditioning, as an adjunct to standard preventive measures, does not improve serum
creatinine levels after contrast administration in patients at risk of contrast induced nephropathy according to
the Dutch guideline.Background: Despite the increasing use of pre- and post-hydration protocols and low osmolar instead of high
osmolar iodine containing contrast media, the incidence of contrast induced nephropathy (CIN) is still signiﬁcant.
There is evidence that contrast media cause ischemia reperfusion injury of the renal medulla. Remote ischemic
preconditioning (RIPC) is a non-invasive, safe, and low cost method to reduce ischemia reperfusion injury. The
aim of this study is to investigate whether RIPC, as an adjunct to standard preventive measures, reduces contrast
induced acute kidney injury in patients at risk of CIN.
Methods: The RIPCIN study is a multicenter, single blinded, randomized controlled trial in which 76 patients at
risk of CIN received standard hydration combined with RIPC or hydration with sham preconditioning. RIPC was
applied by four cycles of 5 min ischemia and 5 min reperfusion of the forearm. The primary outcome measure
was the change in serum creatinine from baseline to 48 to 72 hours after contrast administration.
Results: With regard to the primary endpoint, no signiﬁcant effect of RIPC was found. CIN occurred in four patients
(2 sham and 2 RIPC). A pre-deﬁned subgroup analysis of patients with a Mehran risk score 11, showed a
signiﬁcantly reduced change in serum creatinine from baseline to 48 to 72 hours in patients allocated to the RIPC
group (D creatinine 3.3  9.8 mmol/L) compared with the sham group (D creatinine þ17.8  20.1 mmol/L).
Conclusion: RIPC, as an adjunct to standard preventive measures, does not improve serum creatinine levels after
contrast administration in patients at risk of CIN according to the Dutch guideline. However, the present data
indicate that RIPC might have beneﬁcial effects in patients at a high or very high risk of CIN (Mehran score  11).
The RIPCIN study is registered at: http://www.controlled-trials.com/ISRCTN76496973
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The use of iodine containing contrast media for diagnostic
and therapeutic procedures is the leading cause of hospital
acquired acute kidney injury.1 Despite the increasing use ofof original article: http://dx.doi.org/10.1016/j.ejvs.2015.05.001
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//dx.doi.org/10.1016/j.ejvs.2015.04.002low osmolar instead of high osmolar iodine containing
contrast media and hydration protocols, the incidence of
contrast induced acute kidney injury (CI-AKI) is still signiﬁ-
cant (2e13%).2e7 This so called contrast induced ne-
phropathy (CIN) is deﬁned as an absolute rise of 0.5 mg/
dL and/or a relative increase of 25% in serum creatinine
compared with baseline within 48e72 hours after contrast
administration without an alternative cause of kidney
injury.8 In patients with CIN, 8% require dialysis treatment
and between 22% and 34% die during the index hospitali-
zation.2,9e11 In accordance with international guidelines, all
patients who receive iodine containing contrast media are
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function (estimated glomerular ﬁltration rate [eGFR], based
on the MDRD formula).12,13 Patients with an eGFR <45 mL/
min/1.73 m2, an eGFR 60 mL/min/1.73 m2 with diabetes
mellitus, or an eGFR 60 mL/min/1.73 m2 with two or
more additional risk factors are at high risk of CIN according
to the Dutch guideline.14 For high risk patients, the Dutch
guideline recommends the use of pre- and post-hydration
by saline infusion and the discontinuation of nephrotoxic
medication. Furthermore, 48e72 hours after contrast
administration serum creatinine should be measured.
Despite the identiﬁcation of high risk patients and the use
of hydration protocols, the incidence of CIN still varies be-
tween 2% and 13%.2e7
Although the precise mechanism underlying CIN remains
unknown, evidence exists that contrast media have direct
toxic effects on the tubular cells resulting in altered mito-
chondrial function and apoptosis. Moreover, solid evidence
exists from experimental models that renal ischemia,
resulting from contrast induced vasoconstriction, plays a
key role in the pathogenesis of contrast induced kidney
injury.15,16 The outer part of the medulla has an area with
high oxygen demand and is therefore vulnerable to contrast
induced vasoconstriction of the vasa recta. When vaso-
constriction resolves and the oxygen supply is restored,
post-ischemic cells produce free oxygen radicals. The for-
mation of free radicals contributes at least in part to the
renal tubular cell injury.17 Upon reperfusion, ischemic cells
may become apoptotic because of the opening of mito-
chondrial permeability transition pores.18 Remote ischemic
preconditioning (RIPC) is a short and harmless discontinu-
ation of blood supply to an organ or tissue, followed by
reperfusion, which is applied before the onset of prolonged
ischemia to a distant organ or tissue.19,20 It has been shown
that RIPC induces various kinase cascades that eventually
prevent the opening of mitochondrial permeability transi-
tion pores in the target organ cells, thereby reducing cell
death.18 Moreover, evidence exists that RIPC reduces
oxidative stress by improving antioxidative defense mech-
anisms (e.g. increased superoxide dismutase activity and
glutathione peroxidase) and/or decreasing the generation
of free radicals (e.g. decreased xanthine oxidase activity).21
In animal models and in some clinical trials, RIPC reduces
ischemia reperfusion injury of the kidney.22,23 A pilot study
by Er et al. indicated that RIPC reduced the incidence of CIN
in high risk patients undergoing elective coronary angiog-
raphy.24 However, there was an unusually high incidence of
CIN (40%) in the control group in that study.25 Another
recent study showed that RIPC reduced urinary liver type
fatty acid binding protein (L-FABP), a biomarker for tubulo-
interstitial damage, 24 hours after contrast administration
in patients at low-moderate risk of CIN.26 However, RIPC did
not show beneﬁcial effects on eGFR or the incidence of CIN
in this study. Although, patients enrolled in the study by Er
et al. had a lower mean baseline eGFR (41 vs. 48 mL/min/
1.73 m2), there was considerable overlap in the integer CI-
AKI risk score between the studies. Therefore, the difference
in baseline integer CI-AKI risk score may not fully explain thediscrepancies between the studies. Given the inconclusive
data in literature, a randomized controlled trial was per-
formed to study whether RIPC, as an adjunct to standard
preventive measures, reduces CI-AKI in patients at risk of
CIN.
METHODS
A multicenter, single blinded, randomized controlled trial
was performed at the Radboud University Medical Center
Nijmegen and the Slingeland Hospital Doetinchem. The
RIPCIN study is registered at: http://www.controlled-trials.
com/ISRCTN76496973 and the study protocol has been
published previously.27
Study population
A total of 76 patients were enrolled after written informed
consent was obtained. Sealed envelopes were used to
randomly assign consecutive patients using a 1:1 ratio to
receive either sham preconditioning or RIPC. The study
population consisted of patients at risk of CIN according to
criteria adopted from the Dutch guidelines. Inclusion
criteria were: (1) patients undergoing an interventional or
diagnostic radiological procedure in which they receive an
expected >100 mL intravascular contrast; and (2) patients
who comply with the risk criteria for CIN according to the
Dutch guidelines14: (a) eGFR <45 mL/min/1.73 m2; (b) eGFR
<60 mL/min/1.73 m2 with diabetes mellitus; (c) eGFR
<60 mL/min/1.73 m2; and two additional risk factors from
peripheral vascular disease, heart failure, age >75 years,
anemia, dehydration, diuretics, and non-steroidal anti-in-
ﬂammatory drug use. Exclusion criteria were: (1) age <18
years; (2) hemodialysis or peritoneal dialysis; (3) simulta-
neous participation in another interventional study; (4)
percutaneous coiling/embolization procedures of the kid-
ney; (5) impossibility to perform RIPC, caused by pathology
in both arms (e.g. dystrophy, recent trauma, chronic
wounds); and (6) no written informed consent. An inde-
pendent regional ethics committee, the central committee
on research involving human subjects, Arnhem-Nijmegen,
approved the protocol (number: 41890.091.12; date:
October 16, 2012).
Study protocol
All participating patients received the standard hydration
schedule consisting of intravenous infusion with saline 0.9%
solution 3e4 mL/kg/h for 4 hours prior to and 4 hours after
contrast administration. In patients with congestive heart
failure or eGFR <30 mL/min/1.73 m2, a long schedule was
used with an infusion of saline 0.9% solution 1 mL/kg/h for
12 hours prior to and 12 hours after the contrast adminis-
tration. Nephrotoxic drugs (e.g. diuretics) and metformin
were discontinued 24 hours before and after contrast
administration. Patients in the experimental group of the
study received RIPC by four cycles of ischemia and reperfu-
sion of the forearm by inﬂating a blood pressure cuff around
the upper arm at 50 mmHg above the actual systolic pres-
sure for 5 minutes, followed by 5 minutes of reperfusion. In
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by inﬂating the blood pressure cuff to 10 mmHg below the
actual diastolic pressure during 5 minutes, followed by 5
minutes of reperfusion (four cycles). The time between the
last inﬂation cycle and the start of the intervention was
planned to be within 45 minutes; this time window allowed
performance of the sham or RIPC procedure under calm
conditions on the ward. In the interest of blinding, the
investigator ensured that the inﬂation pressure was not
visible to either the patient or the (interventional) radiolo-
gist. All patients received Xenetrix 300 (0.6e0.85 Osmol/kg
H2O), a low osmolar, non-ionic, and hydrophilic contrast
medium. Patients completed a questionnaire to obtain all
relevant baseline characteristics including (discontinuation
of) medication. Chart review was performed to complement
and double check this information. Blood samples were
taken at baseline and 4e6 hours after contrast administra-
tion. A ﬁnal blood sample was taken 48e72 hours after
contrast administration.Endpoints
The primary endpoint was change in serum creatinine from
baseline to serum creatinine 48e72 hours after contrast
administration. The secondary endpoints were the inci-
dence of CIN (deﬁned as an absolute rise of 0.5 mg/dL or
a relative increase of 25% in serum creatinine over
baseline within 48e72 hours of contrast administration), re-
hospitalization, hemodialysis, and mortality within 6 weeks
of contrast administration.Power analysis
In this randomized study, the change of serum creatinine
from baseline to 48e72 hours after contrast administration102 patients assessed for
eligibility
76 patients randomly assigned
treatment in a 1:1 ratio
38 patients received
Sham preconditioning
38 p
2 patients lost in
follow-up. No
creatinine at day 2-3
36 patients completed follow-up 36 patien
Figure 1. Studywas compared between the experimental and control
groups. Using serum creatinine change as the continuous
response variable increased the power of the study. In a
previous retrospective cohort study at the authors’ center
including 2169 patients at risk of contrast induced ne-
phropathy, serum creatinine values decreased from
120 mmol/L at baseline to 118 mmol/L at 48e72 hours after
contrast administration as a result of adequate hydration
protocols.28,1 This mean change in serum creatinine
(2 mmol/L) was normally distributed with a standard de-
viation of 23 mmol/L. Based on existing evidence, it was
assumed that RIPC with hydration may provide a further
decrease in mean serum creatinine from baseline to 48e72
hours of approximately 14 mmol/L compared with hydration
only. This corresponds with approximately 60% of the effect
found by Er et al.24 If the true difference between the
experimental and control means is 14 mmol/L, then 36
experimental participants and 36 control participants would
be required for the study to be able to reject the null hy-
pothesis with a power of 0.80 and an a of 0.05 calculated
using a one-sided independent t test. In addition, the ex-
pected loss to follow up (e.g. blood sampling not done
between 48 and 72 hours) was approximately 5%. There-
fore, a total of 76 patients was required for inclusion in the
study.
Statistical analysis
The analysis was performed on the basis of intention to
treat principles. Student t test was used to compare nor-
mally distributed variables, and ManneWhitney U test was
used to compare non-normally distributed continuous data.
In a previously published trial protocol,23 a subgroup anal-
ysis was deﬁned to assess whether the impact of RIPC on
the primary endpoint is affected by the Mehran risk score.29to
atients received
RIPC
- 2 patients had arm pathology
- 24 patients gave no informed consent
2 patients lost in
follow-up. No
creatinine at day 2-3
ts completed follow-up
ﬂow chart.
Table 1. Baseline characteristics.
Sham group
(n ¼ 36)
RIPC group
(n ¼ 36)
p
Age, y 73  8.5 71  11 .37
Male sex, n (%) 21 (58) 14 (39) .16
BMI kg/m2 27  4.7 29  5.6 .22
Contrast administration
Diagnostic 18 (50) 21 (58)
Treatment 18 (50) 15 (42) .64
Underlying disease
Diabetes 10 (28) 8 (22) .58
Peripheral vascular disease 21 (58) 20 (56) .64
Myocardial infarction 16 (44) 13 (36) .46
Heart failure 8 (22) 7 (19) .78
Brain infarction 5 (14) 4 (11) .73
TIA 7 (19) 6 (17) .76
Anemia 5 (14) 3 (8) .47
Hypertension 24 (67) 28 (78) .59
Malignancy 8 (22) 7 (19) .77
Vital signs
Systolic (mmHg) 137  17 144  20 .12
Diastolic (mmHg) 75  10 76  11 .82
Heart rate (beats/min) 68  13 69  12 .75
Hydration protocol
Short 31 (86) 31 (84)
Long 5 (14) 5 (14) .60
Baseline serum creatinine,
mmol/L
119  32 115  27 .50
Baseline eGFR mL/min/1.73 m2 52  13 51  11 .87
Volume of contrast used, mL 98  29 99  29 .85
Time between last inﬂation and
contrast administration, min
44  36 46  23 .83
Integer CI-AKI risk score
Mean (Q1eQ3) 6 (2e9) 6 (2e9) 1.00
Integer CI-AKI risk score
<5 15 (42) 17 (47)
6e10 16 (44) 13 (36)
>11 5 (14) 6 (17) .91
Data given as mean  SD, n (%), or as speciﬁed.
BMI ¼ body mass index; CI-AKI ¼ contrast induced acute kidney
injury; eGFR ¼ estimated glomerular ﬁltration rate;
RIPC ¼ remote ischaemic preconditioning; TIA ¼ transient
ischemic attack; y ¼ years.
Table 2. Baseline cardiovascular medication.
Sham group
(n ¼ 36)
RIPC group
(n ¼ 36)
p
Platelet aggregation inhibitors 20 (56) 14 (39) .24
Coumarin 9 (25) 8 (22) 1.00
NSAID 0 (0) 2 (3) .49
Beta blocker 23 (64) 24 (67) 1.00
Isosorbide dinitrate 8 (22) 3 (8) .19
Calcium channel blocker 8 (22) 12 (33) .43
Angiotensin converting enzyme
inhibitor
13 (36) 9 (25) .44
Angiotensin II receptor blocker 11 (31) 8 (22) .59
Loop/thiazide diuretics 24 (67) 15 (42) .10
Spironolactone 3 (8) 3 (8) 1.00
Data given as n (%).
RIPC ¼ remote ischaemic preconditioning; NSAID ¼ non-steroidal
anti-inﬂammatory drug.
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according to their Mehran risk score (i.e. (1) risk score 5;
(2) risk score 6e10; (3) risk score 11). Statistical analyses
were performed with SPSS 20.0. A probability value of <.05
was considered to indicate statistical signiﬁcance.
RESULTS
A total of 102 patients was assessed for eligibility, but 26
patients did not fulﬁll the inclusion criteria (Fig. 1). Seventy-
six patients were randomly allocated to receive sham pre-
conditioning or RIPC in a 1:1 ratio. Four patients, two in the
sham group and two in the RIPC group, were excluded after
randomization because blood sampling 48e72 hours after
contrast administration was not performed. A total of 72
patients completed follow up of the study. There were no
signiﬁcant differences in baseline characteristics or cardio-
vascular medication between the experimental and control
groups (Tables 1 and 2).
Trial outcomes
With regard to the primary study endpoint (i.e. change in
serum creatinine from baseline to 48e72 hours after
contrast administration), no signiﬁcant effect of RIPC was
found (Table 3). CIN occurred in four patients (2 sham and 2
RIPC) and their respective Mehran risk scores were 1, 2, 6,
and 14. None of the patients required dialysis or re-
hospitalization. Two patients (1 with CIN) died within 6
weeks of the intervention. No adverse events occurred
because of the preconditioning protocols. A subgroup
analysis, in which all patients were classiﬁed according to
their Mehran risk score, showed a signiﬁcantly reduced
change in serum creatinine in patients with a Mehran risk
score 11 allocated to the RIPC group compared with the
sham group (Table 4).
DISCUSSION
The present study demonstrates that RIPC, induced by
intermittent upper arm ischemia before diagnostic and
therapeutic intravascular contrast procedures, does not
reduce contrast induced kidney injury in patients who are at
risk of developing CIN according to the Dutch guideline.14
However, the data indicate that a subgroup of patients
who are at high to very high risk of developing CI-AKI, may
beneﬁt from RIPC as an adjunctive preventive measure.
Therefore, the ﬁndings do not necessarily contradict results
from previous studies in which RIPC was found to alleviate
CI-AKI.24,26 Er et al. investigated the effects of RIPC in pa-
tients with a (very) high risk of developing CIN according to
the risk classiﬁcation system developed by Mehran et al.
This best validated risk score includes both clinical and
procedural variables and is divided into four risk classes of
developing CI-AKI: low (risk score 5), moderate (risk score
6e10), high (risk score 11e15), and very high (risk score
16). In the study by Er et al., 60% of the participants were
at high or very high risk of developing CI-AKI, whereas
Igarashi et al. included only 6% of these (very) high risk
patients.24,26 In the present study, 15% were at high or very
Table 3. Trial outcomes.
Sham group (n ¼ 36) RIPC group (n ¼ 36) p
Primary endpoint
Change in serum creatinine from baseline to 48e72 hr, mmol/L 0.3  14.7 0.25  14.6 .87
Secondary endpoints
Change in serum creatinine from baseline to 4e6 hr, mmol/L 14.5  11.8 11.4  11.0 .26
Contrast induced nephropathy, n (%) 2 (6) 2 (6) 1.00
Re-hospitalization within 6 wk 0 (0) 0 (0) n.a.
Dialysis within 6 wk 0 (0) 0 (0) n.a.
Mortality within 6 wk 2 (6) 0 (0) 0.49
Data given in mean  SD, n (%).
RIPC ¼ remote ischaemic preconditioning; wk ¼ weeks.
Table 4. Change in serum creatinine per group divided by Mehran
risk score.
Mehran risk
score
n Group Change in serum
creatinine (mean  SD)
p
<5 32 Sham (n ¼ 15) 0.2  14.2
RIPC (n ¼ 17) 0.9  13.1 .83
6e10 29 Sham (n ¼ 16) 6.1  8.2
RIPC (n ¼ 13) 1.1  18.6 .18
11 11 Sham (n ¼ 5) 17.8  20.1
RIPC (n ¼ 6) 3.3  9.8 .048
RIPC ¼ remote ischaemic preconditioning.
Remote Ischemic Preconditioning 531high risk of developing CI-AKI. In line with these ﬁndings,
Igarashi et al. did not ﬁnd a reduction in creatinine based
CI-AKI. Although their ﬁnding, that RIPC reduced the inci-
dence of L-FABP based CI-AKI, provides interesting proof of
concept evidence, its clinical relevance remains to be
established. With regard to the study by Er et al., it should
be noted that based on the reported Mehran risk score, the
incidence of CIN should lie between 26% and 30% rather
than 40% in the control group.25 Although the authors
attributed this discrepancy to the high prevalence of heart
failure and diabetes in their cohort, the question arises
whether the standard preventive measures (i.e. hydration
and discontinuation of nephrotoxic drugs) were carried out
appropriately. Nevertheless, the results of the present
subgroup analysis support the hypothesis that RIPC reduces
the incidence of creatinine based CI-AKI in patients who are
at high or very high risk of developing CI-AKI.
With regard to the preconditioning protocol, the present
study used a similar protocol to that of the studies by Er
et al.24 and Igarashi et al.,26 consisting of four cycles of 5
minutes inﬂation of a blood pressure cuff around the upper
arm and 5 minutes deﬂation. This protocol is relatively
“standard” and has been used in many clinical trials. A
recently performed meta-analysis investigating the effect of
RIPC on ischemia reperfusion injury on animal kidneys, did
not reveal a signiﬁcant difference in efﬁcacy between RIPC
protocols using repeated short cycles of ischemia (frac-
tionated stimulus) and those using one (usually) longer
continuous ischemic stimulus.22 To date, human data
comparing the efﬁcacy of different RIPC protocols are very
scarce and there is no convincing evidence that justiﬁes the
use of an alternative RIPC protocol for clinical trials.
The major strengths of this study are related to its design
as a blinded, sham controlled study with a registered andpreviously published study protocol. All physicians, nursing
staff, and radiology personnel were blinded to the alloca-
tion of treatment. This minimized the risk of bias because of
altered adherence to other preventive measures including
saline infusion, and discontinuation of diuretics and met-
formin, as both patients and nursing staff were unaware
of the allocation of treatment. Physicians and radiology
personnel, responsible for the amount of contrast used,
were also blinded. As inclusion criteria were not conﬁned to
patients with low to moderate or high to very high risk of
developing CIN, the present study cohort reﬂects routine
clinical practice very well.
There are several limitations to this study. First, as serum
creatinine levels generally peak between 48 and 72 hours
after contrast administration, it would have been ideal to
measure serum creatinine at both 48 and 72 hours. How-
ever, in practice most patients were discharged within 24
hours of the contrast procedure. Those patients were asked
to visit the outpatient clinic or their general practitioner for
blood sampling at 48 or 72 hours after contrast adminis-
tration. Sampling at both time points would severely in-
crease the burden for the participants. It is also important
to note that blood samples taken by the general practitioner
were analyzed outside the authors’ institution. Although
slight variability between the different laboratories cannot
be ruled out, it is not expected that this inﬂuenced results
signiﬁcantly. Second, this was a relatively small study with
small numbers available for subgroup analysis. Although this
subgroup analysis has been described in a previously pub-
lished study protocol, its outcome should be interpreted
with care. Third, a certain inﬂuence of the sham RIPC
treatment, by inﬂating a cuff 10 mmHg below the actual
diastolic pressure, cannot be ruled out. As the sham inﬂa-
tion around the upper arm only restricts blood ﬂow to a
very limited extent, this theoretical disadvantage does not
outweigh the risk of bias related to a study design without
adequate blinding. Finally the incidence of CIN was not used
as the primary endpoint. Given the low incidence of CIN in
patients who are at risk according to the Dutch guidelines
(approximately 2%), use of this as the endpoint would
require a trial with a very large number of participants.
Therefore, the change in serum creatinine from baseline to
48e72 hours was used as the primary endpoint. However,
the clinical relevance of improved serum creatinine levels in
those patients remains to be elucidated.
532 T.P. Menting et al.In conclusion, the results from this randomized controlled
trial show that RIPC, as an adjunct to standard preventive
measures, does not reduce CI-AKI in patients at risk of CIN
according to the Dutch guideline. However, it is proposed
that RIPC might have clinical beneﬁts in patients with a high
or very high risk of CIN, and this should be pursued in new
clinical trials.
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